insights_auto
Pse është rritur OPHLY 5,91%?
Zhytu më thellëchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,92 US$
arrow_upward
+5,91%(+0,28) 1D
15 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për OPHLY...
Hap
4,96 US$
I lartë
4,96 US$
I ulët
4,90 US$
Kapitalizimi i tregut
1,20 bln
Vëllimi mesatar
61,54 mijë
Vëllimi
68,37 mijë
Maksimumi 52-javor
5,75 US$
Minimumi 52-javor
3,82 US$
Beta
0,21
Aksionet në qarkullim
1,50 mld
Numri i punonjësve
4 mijë
Hap
4,96 US$
I lartë
4,96 US$
I ulët
4,90 US$
Kapitalizimi i tregut
1,20 bln
Vëllimi mesatar
61,54 mijë
Vëllimi
68,37 mijë
Maksimumi 52-javor
5,75 US$
Minimumi 52-javor
3,82 US$
Beta
0,21
Aksionet në qarkullim
1,50 mld
Numri i punonjësve
4 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
PR Newswire UK
·
6 minuta më parë
BCRF Launches $100 Million Venture Program for Breast Cancer: NYSE Content Update
Quiver Quantitative
·
49 minuta më parë
Private Bancorp of America Reports Third Quarter 2026 Net Income of $11.4 Million and Diluted EPS of $1.97 as Deposits and Loans Grow After NASDAQ Uplisting
www.marketscreener.com
·
31 minuta më parë
TruGolf Holdings Inc. (NASDAQ: TRUG) Acquisition Positions Company in Market for Regulated Tokenization, Digital Securities Infrastructure
Profili
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Rreth Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Drejtori ekzekutivGyo Sagara | Gyo Sagara
Punonjësit4,21 mijë
Themeluar më1717
SeliaOsaka, Osaka, Japoni
Sektori-
Uebsajtiono-pharma.com